From: Prospective evaluation of intravitreal bevacizumab for ischemic central retinal vein occlusion
Study | Type of CRVO | Eyes | Baseline visual acuity, logMAR | 6 month visual acuity, logMAR | Baseline CFT, μm | 6 month CFT, μm |
---|---|---|---|---|---|---|
Our study | iCRVO only | 9 | 1.3 (1 to HM) | 1.7 (1.3 to NLP) | 858 ± 311 | 243 ± 106 |
Prigliner et al. [12] | iCRVO only | 17 | 1.52 ± 0.34 | 1.06 ± 0.45 | 534 ± 193 | 279 ± 127 |
Costa et al. [17] | iCRVO and non-iCRVO | 7 | 1.21 ± 0.36 | 0.68 ± 0.32 | 730 ± 257 | 260 ± 135 |